NOTTINGHAM, UK — In a population-based cohort of patients with type 2 diabetes who were seen in the past decade in clinical practices in the UK, those who received thiazolidinediones (TZDs or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback